BRIEF — Janssen secures Symtuza funding from NHS England

NHS England (NHSE) will provide funding for Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with a body weight of at least 40 kg.

The news has been welcomed by the drug’s developer, Janssen, part of the Johnson & Johnson group.

Jennifer Lee, director of health economics, market access and reimbursement and advocacy at Janssen-Cilag, said: “We are delighted that NHSE has provided vital funding for this treatment option; enabling access for individuals who require a darunavir-based STR to effectively control their HIV, with the potential to support adherence to treatment.”